NSEInvestor Presentation18 Jun 2026 · 18 Jun 2026, 09:52 am

Investor Presentation

Procter & Gamble Health Limited · PGHL

✦ AI Summary▲ PositiveResults

Procter & Gamble Health Limited has informed the Exchange about Investor Presentation, highlighting strong FY 2025-26 performance, integrated growth strategy, and portfolio performance drives brand choice superiority.

Analysis Scores

Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Procter & Gamble Health Limited has informed the Exchange about Investor Presentation

Attachments (1)

📄

PGHL_18062026095119_PGHL__Analyst_Meet_-Presentation.pdf

pdf

Download →
View document text
Date : June 18, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001 Mumbai – 400051 Ref:- Scrip ID: - 500126 Ref:- Scrip Code:- PGHL Dear Sir / Madam, Sub: Analysts/Institutional Investors – Presentation This has reference to the intimation dated June 4, with respect to the virtual connect with analysts/ institutional investors to be held today, Thursday, June 18, 2026, at 2:30 p.m. (IST). Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the presentation for the above meeting with analysts/ institutional investors. This is for your record. Thanking you, Yours faithfully, For Procter & Gamble Health Limited Zeal Rupani Company Secretary Investor and Analyst Presentation 18 June 2026 Disclaimer This communication, except for the historical data, may contain forward-looking statements, including words, phrases, numbers that set forth anticipated results based on management’s current plans and assumptions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except to the extent required by law. Investor and Analyst Presentation 18 June 2026 AGENDA • Business Results • Strategy and Fiscal Updates • Long term trends • Landscape Fiscal Results 2025-26 DELIVERED A STRONG YEAR FY 2025-26 Strong, consistent Balanced Growth 16 +30% SALES PAT Considering that the company, effective last year, changed its Financial Year from July 1 –June 30 to April 1 – March 31, the last Financial Year of the Company covered a period of 9 months, from July 1, 2024, to March 31, 2025. The company performance has therefore been indexed versus the comparable 12-months period in the last year (April 1,2024, to March 31, 2025). The performance versus a 9-month past fiscal will not be comparable. INTEGRATED GROWTH STRATEGY PORTFOLIO PERFORMANCE DRIVES BRAND CHOICE SUPERIORITY ORGANIZATION TO WIN WITH CONSUMERS EMPOWERED • AGILE ACCOUNTABLE CONSTRUCTIVE DISRUPTION PRODUCTIVITY ACROSS OUR BUSINESS TO FUEL INVESTMENTS PORTFOLIO PERFORMANCE DRIVES BRAND CHOICE VITAMIN B IRON VITAMIN E (Nerve Health) PORTFOLIO VITAMIN B Trusted, Quality, Highly NASAL CARE OMEGA - 3 COMPLEX Recommended Brands SUPERIORITY TO WIN WITH CONSUMERS SUPERIORITY TO WIN WITH CONSUMERS RETAIL PRODUCT PACKAGING COMMUNICATION CONSUMER & EXECUTION CUSTOMER VALUE Superior Innovations To Delight Consumers PRODUCT Easy-To-Consume Symptomatic Relief Superior Iron Supplement from Nerve Pain Fatty Liver Solution Packaging that educates, and stands out in store PACKAGING BEFORE AFTER LIG Copy with subs RETAIL EXECUTION PRODUCTIVITY TO FUEL INVESTMENTS PRODUCTIVITY INTEGRATED INTO THE STRATEGY Delivering the same or better output measures… with lower spending or resource investment. AD SPEND & MATERIALS MANUFACTURING OVERHEAD PROMOTION INR 35 crores productivity savings for FY 25/26 CONSTRUCTIVE DISRUPTION ACROSS THE BUSINESS CONSTRUCTIVE DISRUPTION ACROSS THE BUSINESS Health Care Practitioners/ LEVERAGING EXTRA URBAN Health Care EMERGING COVERAGE Organizations / CHANNELS EXPANSION Chemist + (E-pharmacies, E-com, Q-Com) DISTRIBUTOR PARTNERSHIPS Winning model enabling Available to consumers Expanding reach to white- last mile reach where they are space extra urban markets ORGANIZATION EMPOWERED • AGILE • ACCOUNTABLE Prioritizing Employee Wellbeing Delivering Superior Employee Value Equation OUR FOCUS AREAS Healthcare Healthcare Accessibility Awareness Improving Creating Healthcare healthcare SUPPORTING ACCESS TO HEALTH accessibility awareness for CARE FACILITIES AND AWARENESS IN through mobile uptake of UNDERSERVED COMMUNITIES medical units Nutrition, Hygiene SINCE 2019 across 11 states & maternal care Partners 15,00,000+ Lives impacted DRIVING HEALTHCARE ACCESS Mobile Health Care Units Special Boat Clinic 1.8+L 1.1+L 25+K Free Treatments Kilometers VISITS FY26 Travelled DRIVING HEALTHCARE AWARENESS Yes To Poshan Initiative Healthcare For Children 55K 4000+ ~20K 30+ Lives Malnourished Children CCIs Supported Villages Impacted Children Impacted Each Year LONG TERM TRENDS SUPERIOR RESULTS OVER THE PAST 5 YEARS 7 +42% + % + % CAGR CAGR Increase in NET SALES Note: 1) Basis Published results; 2) Net Sales refers to revenue from operations; 3) PAT Excluding OCI; 4) ROE = PAT/ Avg. Equity SUPERIOR RESULTS OVER THE PAST 5 YEARS REVENUE FROM OPERATIONS (in INR Crs) PAT (in INR Crs) 1,408 1,008 2021 2022 2023 2024 2025* 2026 2021 2022 2023 2024 2025* 2026 Note: 1) *FY 24-25 was a 9-month year due to Fiscal Year change. For comparability, considered 12-month period from Apr 24 to Mar 26. 2) Basis Published results; 3) Net Sales refers to revenue from operations; 4) PAT Excluding OCI [PAT – Profit After Tax; OCI – Other Comprehensive Income] CREATING SUPERIOR SHAREHOLDER VALUE July 2016 Oct 2017 Jan 2019 Apr 2020 July 2021 Oct 2022 Jan 2024 Apr 2025 Mar 2026